Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ http://cyberleninka....arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Фармакоэкономический подход к формированию перечня лекарственных препаратовв терапии бронхиальной астмы у детей

Фармакоэкономический подход к формированию перечня лекарственных препаратовв терапии бронхиальной астмы у детей

Abstract

С целью удовлетворения потребности в рациональном и более эффективном использовании ресурсов выявлены группы высокоэффективных препаратов и препаратов, имеющих ярко выраженный комплекс побочных эффектов. На основе результатов метода экспертной оценки и фармакоэкономических исследований разработан перечень лекарственных препаратов для терапии бронхиальной астмы у детей, включающий 10 фармакотерапевтических групп.

To fulfill the need for rational and more effective use of resources there has been determined groups of highly effective preparations and medicines with a pronounced set of side effects. The results of the expert assessment method and pharmacoeconomic investigations allowed to develop the list of medicines consisting of 10 pharmacotherapeutic groups for treatment of bronchial asthma in children.

Keywords

БРОНХИАЛЬНАЯ АСТМА, ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ, ЭКСПЕРТНАЯ ОЦЕНКА, ФАРМАКОЭКОНОМИЧЕСКИЕ ИССЛЕДОВАНИЯ

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Related to Research communities